The Blavatnik Fund for Innovation at Yale
Accelerating the translation of early-stage life science research into impactful products.
Since 2017, Yale has supported 107 projects with over $28 million in direct funding through the Blavatnik Fund for Innovation.
The Blavatnik Fund for Innovation at Yale is a $65 million fund, committed to cultivating and transforming Yale's pioneering research into cutting-edge, life-saving solutions within the realm of life sciences. The Fund is made possible by a generous grant from the Blavatnik Family Foundation in support of the commercialization of Yale faculty applied research and technology in the life sciences. The Fund’s integrated approach combines business expertise, intensive guidance, and essential funding to support innovative, Yale investigator-initiated translational research. Completed projects will be better positioned to positively impact human health through startup advancement, partnerships with industry, major industry-sponsored research agreements, and/or external non-dilutive funding.
blavatnik applications
We are currently open for applications for the Spring 2026 Accelerator Awards. Deadline to apply is April 30th.
Blavatnik By The Numbers
Last Updated: 2/12/2026
107
Funded Projects
47
Biotech Ventures Launched
101
Faculty that have received awards including co-PIs (87 Lead PIs)
$28M+
Total Awards
$470M
Raised by Ventures
>350
Patents associated with Blavatnik-Funded technologies
9
FDA Investigational New Drug (IND) Status
8
Clinical Trials Initiated
2025 Overview
2025 Highlights
- $3.4M in awards: 23 awards in 17 therapeutic areas
- $101M raised across all startups
- 7 new startups founded
2025 Annual Report